TESARO Inc (TSRO) is Reiterated by RBC Capital Mkts to Outperform, Raises Price Target to $ 128

TESARO Inc (TSRO) was Reiterated by RBC Capital Mkts to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 128 from a previous price target of $122 . RBC Capital Mkts advised their investors in a research report released on Oct 10, 2016.

Many Wall Street Analysts have commented on TESARO Inc. Company shares were Reiterated by FBR & Co. on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 115 from a previous price target of $102 .Lake Street Resumed TESARO Inc on Sep 6, 2016 to “Buy”, Price Target of the shares are set at $114.BofA/Merrill Initiated TESARO Inc on Aug 30, 2016 to “Neutral”, Price Target of the shares are set at $97.

On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.

TESARO Inc closed down -0.63 points or -0.63% at $99.26 with 13,64,709 shares getting traded on Friday. Post opening the session at $100.21, the shares hit an intraday low of $96.52 and an intraday high of $101.6 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Sep 23, 2016, Martin H. Jr. Huber (SVP & Chief Medical Officer) sold 408 shares at $108.12 per share price. According to the SEC, on Sep 9, 2016, Edward C English (V.P.Finance and Administration) sold 7,000 shares at $89.15 per share price. On Sep 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 29,166 shares at $86.04 per share price, according to the Form-4 filing with the securities and exchange commission.

TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.


Leave a Reply

TESARO Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on TESARO Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.